Information Provided By:
Fly News Breaks for June 27, 2017
BLUE
Jun 27, 2017 | 07:32 EDT
SunTrust analyst Edwrad Nash says that data on bluebird's Lenti-D drug in Cerebral Adrenoleukodystrophy was positive. He thinks that it "provides strong support" for the approval of the drug, and he keeps a Buy rating on the stock.
News For BLUE From the Last 2 Days
There are no results for your query BLUE